Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT04786106

Investigation of Surgery, Collagenase, and Restorex for the Improvement of Peyronie's

The purpose of this study is to compare key clinical outcomes of collagenase clostridium histolyticum injections versus surgery for the management of Peyronie's Disease.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Age range

18 year and older

Sex eligibility

Male

Study type

Interventional

Phase

Phase 4

Primary location

The Male Fertility and Peyronie's Clinic

Orem, Utah, 84057, United States

About this study

After eligible patients have been informed about the study protocol and risks and consent have been given, men will be randomly assigned into either the collagenase clostridium histolyticum + penile traction therapy (CCH + PTT) group or to the surgery + penile traction therapy (surgery + PTT) group. Those in the CCH + PTT group will receive the full 4 series of 8 Xiaflex injections with 1-3 days between each set of 2 injections and 6 weeks prior to the next series. Patients would then use the RestoreX traction device throughout the series to 3 months post-treatment. Those that were assigned the surgery + PTT treatment protocol would undergo surgery using either penile plication or incision and grafting, depending on the degree of curvature and erectile function. Traction using RestoreX will also be prescribed to these men 2-4 weeks post-operatively until 3 months post-treatment. Key clinical outcomes of both treatment protocols will be compared.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Men with PD
  • >18 years old
  • Curvature ≥30 degrees
  • Ability to achieve an erection satisfactory for intercourse with or without PDE5 inhibitors

Exclusion criteria

  • Prior treatment with CCH or surgery
  • Moderate (shadowing) or severe (>1 cm) penile calcification
  • Any contraindications to CCH, PTT, or surgery - as determined by the PI

Treatment and study plan

Collagenase Clostridium Histolyticum 0.9 MG [Xiaflex] (CCH)

Drug

Men in this cohort would receive the full series of 8 Xiaflex injections: 2 injections separated by 1-3 days, repeated 3 additional times with 6 week breaks between treatments.

Other names: Xiaflex

Penile Plication Surgery

Procedure

Men in this cohort would undergo surgery using either penile plication or incision and grafting. The specific surgery would be selected based on commonly used criteria: plication for curvatures <70 degrees; I&G used for ≥70 degrees or severe hourglass / hinge deformities. However, the specific surgery (plication vs I&G) will ultimately be decided based on the primary investigator's clinical judgment.

Incision and Grafting (I&G) Surgery

Procedure

Men in this cohort would undergo surgery using either penile plication or incision and grafting. The specific surgery would be selected based on commonly used criteria: plication for curvatures <70 degrees; I&G used for ≥70 degrees or severe hourglass / hinge deformities. However, the specific surgery (plication vs I&G) will ultimately be decided based on the primary investigator's clinical judgment.

RestoreX Penile Traction Device

Device

RestoreX is a Class I PTT device developed by PathRight Medical, is registered with the FDA, and has randomized controlled data demonstrating efficacy when used for the treatment of PD.

Primary outcomes

  1. Overall satisfaction with treatment

    Time frame: 1 year

    Answer to SAPS question #1 (How satisfied are you with the effect of your treatment?) to determine overall satisfaction at all time points

  2. Subjective reporting of erectile dysfunction post treatment

    Time frame: 1 year

    Comparison of erectile dysfunction complication rates

  3. Subjective reporting of changes in penile sensation post treatment

    Time frame: 1 year

    Comparison of changes in penile sensation complication rates

  4. Subjective reporting of changes in penile length post treatment

    Time frame: 1 year

    Comparison of perceived changes in penile length complication rates

  5. International Index of Erectile Function, Erectile Function Domain (IIEF) Scores

    Time frame: 1 year

    Comparison of IIEF erectile function domain score (Q1-5, 15; min/max 1-30; higher is better)

Secondary outcomes

  1. Peyronie's Disease Questionnaire (PDQ) Scores

    Time frame: 1 year

    Comparison of PDQ questionnaire scores; Subdomains - psychological and physical (Q1-6; min/max 0-24; lower is better), penile pain (Q7-9; min/max 0-30; lower is better), symptom bother (Q10-15; min/max 0-16; lower is better)

  2. International Index of Erectile Function (IIEF) Scores

    Time frame: 1 year

    Comparison of IIEF questionnaire scores-all domains except erectile function (which is a primary endpoint); subdomains: orgasmic function (Q9-10; min/max 0-10; higher is better), sexual desire (Q11-12; min/max 2-10; higher is better), intercourse satisfaction (Q6-8; min/max 0-15; higher is better), overall satisfaction (Q13-14; min/max 2-10; higher is better)

  3. Beck's Depression Inventory (BDI) Scores

    Time frame: 1 year

    Comparison of BDI questionnaire scores on depression. 21 items (min/max 0-63, lower is better)

  4. Penile Curvature

    Time frame: 1 year

    Comparison of changes in penile curvature

  5. Objective measurements of penile length post treatment (compared to pre-treatment)

    Time frame: 1 year

    Comparison of changes in penile length

  6. Interventions required

    Time frame: 1 year

    Comparison of subsequent interventions required - surgery or CCH injections

  7. Hospitalizations

    Time frame: 1 year

    Number of hospitalizations or ER visits resulting from treatment

  8. Non-standardized questionnaire

    Time frame: 1 year

    Comparison of non-standardized questionnaire responses

Sponsors and collaborators

Lead sponsor

Charitable Union for the Research and Education of Peyronie's Disease

Other

Collaborators

  • Endo USA Inc., a Keenova Therapeutics Company

Registry information

Official study title

Comparison of Collagenase Clostridium Histolyticum to Surgery for the Management of Peyronie's Disease: A Randomized Trial

Acronym: iSCRIP

Important dates

Study start
2020
Primary completion
2027
Study completion
2027
First posted
Mar 8, 2021
Registry last updated
Feb 13, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.